KRAS and lung cancer: Our results showed that the cell growth inhibition rates of the HOXC10 inhibition reached 53.2%–85.3% compared to those of the empty vector group of KRAS-mutant lung cancer bone metastasis cells, according to colony formation, CCK8, LDH release, and EDU assays (Fig. 2a and Fig. S1A–D).